Shikonin induces apoptosis and G0/G1 phase arrest of gallbladder cancer cells via the JNK signaling pathway.

Shikonin, a natural product isolated from the roots of Lithospermum erythrorhizon, is considered to have antitumor effects. Gallbladder cancer (GBC) is a prevalent biliary tract malignancy with few curative therapeutic stragegies and poor prognosis. In the present study, we detected the effects of shikonin on GBC cells as well as the underlying molecular mechanisms. The results demonstrated that GBC cell proliferation was inhibited by shikonin as determined by MTT and colony formation assays. Flow cytometry results demonstrated that shikonin treatment enhanced apoptosis and promoted G0/G1 phase arrest in the GBC cells. Western blot assay showed that shikonin induced mitochondrial-dependent apoptosis via the JNK signaling pathway. Moreover, shikonin suppressed tumor growth in mice bearing GBC-derived xenografts in a dose‑dependent manner without side-effects. These results revealed that shikonin exhibits anticancer effects on GBC cells by inducing apoptosis and regulating the cell cycle. Taken together, shikonin may be a novel and safe chemotherapeutic agent for the treatment of GBC.

[1]  W. Lu,et al.  MicroRNA-29c-5p suppresses gallbladder carcinoma progression by directly targeting CPEB4 and inhibiting the MAPK pathway , 2017, Cell Death and Differentiation.

[2]  Ho-Joon Lee,et al.  Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300. , 2016, Biochimica et biophysica acta.

[3]  J. Qian,et al.  A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1 , 2016, Science.

[4]  Hui Zhao,et al.  eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma , 2016, Oncotarget.

[5]  Zheng Wang,et al.  The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR , 2016, Journal of experimental & clinical cancer research : CR.

[6]  H. Weng,et al.  miR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinoma , 2016, Oncotarget.

[7]  Yanmin Zhang,et al.  Shikonin induces apoptosis of HaCaT cells via the mitochondrial, Erk and Akt pathways , 2016, Molecular medicine reports.

[8]  L. Roberts,et al.  Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. , 2016, Chinese clinical oncology.

[9]  Yubo Xie,et al.  Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo. , 2016, Biochemical and biophysical research communications.

[10]  Jin‐Young Jang,et al.  Effects of Surgical Methods and Tumor Location on Survival and Recurrence Patterns after Curative Resection in Patients with T2 Gallbladder Cancer , 2016, Gut and liver.

[11]  Nandini A. Sahasrabuddhe,et al.  Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer , 2015, BMC Cancer.

[12]  Yunhui Liu,et al.  Shikonin Inhibits the Migration and Invasion of Human Glioblastoma Cells by Targeting Phosphorylated β-Catenin and Phosphorylated PI3K/Akt: A Potential Mechanism for the Anti-Glioma Efficacy of a Traditional Chinese Herbal Medicine , 2015, International journal of molecular sciences.

[13]  J. Qian,et al.  β-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling , 2015, Oncology letters.

[14]  Mao-mao Zhu,et al.  Shikonin inhibits the cell viability, adhesion, invasion and migration of the human gastric cancer cell line MGC‐803 via the Toll‐like receptor 2/nuclear factor‐kappa B pathway , 2015, The Journal of pharmacy and pharmacology.

[15]  W. Wu,et al.  MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer , 2015, Oncotarget.

[16]  You Li,et al.  Shikonin causes cell-cycle arrest and induces apoptosis by regulating the EGFR–NF-κB signalling pathway in human epidermoid carcinoma A431 cells , 2015, Bioscience reports.

[17]  H. Weng,et al.  SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway , 2015, Molecular Cancer.

[18]  W. Lu,et al.  Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway , 2014, Nature Genetics.

[19]  G. Eslick,et al.  Systematic review with meta‐analysis: the relationship between chronic Salmonella typhi carrier status and gall‐bladder cancer , 2014, Alimentary pharmacology & therapeutics.

[20]  B. Han,et al.  Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway. , 2014, Biochemical pharmacology.

[21]  Y. Wang,et al.  Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2 , 2011, Oncogene.

[22]  Di Chen,et al.  Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo , 2009, International journal of cancer.

[23]  P. Oettgen,et al.  Mechanism of inhibition of tumor angiogenesis by β‐hydroxyisovalerylshikonin , 2009, Cancer science.

[24]  Yoshimasa Nakamura.  Chemoprevention by isothiocyanates: molecular basis of apoptosis induction. , 2009, Forum of nutrition.

[25]  D. Camidge,et al.  Targeted manipulation of apoptosis in cancer treatment. , 2008, The Lancet. Oncology.

[26]  Z. Jian,et al.  Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-kappaB pathway. , 2008, Phytotherapy research : PTR.

[27]  H. Niida,et al.  Genetic instability in cancer cells by impaired cell cycle checkpoints , 2006, Cancer science.

[28]  Yi Chen,et al.  SH‐7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor , 2006, International journal of cancer.

[29]  Yong Yang,et al.  Involvement of bax/bcl-2 in wogonin-induced apoptosis of human hepatoma cell line SMMC-7721 , 2006, Anti-cancer drugs.

[30]  M. Lebwohl,et al.  Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. , 2003, Cancer letters.

[31]  C. Rice-Evans,et al.  c-Jun N-terminal kinase (JNK)-mediated modulation of brain mitochondria function: new target proteins for JNK signalling in mitochondrion-dependent apoptosis. , 2003, The Biochemical journal.

[32]  Seamus J. Martin,et al.  Portrait of a killer: the mitochondrial apoptosome emerges from the shadows. , 2003, Molecular interventions.

[33]  Xin Chen,et al.  Cellular pharmacology studies of shikonin derivatives , 2002, Phytotherapy research : PTR.

[34]  G. Núñez,et al.  Caspases: the proteases of the apoptotic pathway , 1998, Oncogene.

[35]  D. Henson,et al.  Liver, gallbladder, extrahepatic bile ducts, and pancreas , 1995, Cancer.

[36]  M. Hayashi.  [Pharmacological studies of Shikon and Tooki. (2) Pharmacological effects of the pigment components, Shikonin and acetylshikonin]. , 1977, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.